isopropenylboronic acid pinacol ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 英文名称: isopropenylboronic acid pinacol ester
• 英文别名: (3-Hydroxy-2,3-dimethylbutan-2-yl)oxy-prop-1-en-2-ylborinic acid
• 化学式: C₉H₁₉BO₃
• 分子量: 186.059
• InChiKey: WDGVTXBJDZSBHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.15
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  isopropenylboronic acid pinacol ester 、 methyl 2-(tert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-6-methyl-3-trifluoromethanesulfonyloxy-phenyl]acetate 以 1,4-二氧六环 、 水 为溶剂， 生成 methyl 2-(tert-butoxy)-2-[2-(3,4-dihydro-2H-1-benzopyran-6-yl)-3-isopropenyl-6-methylphenyl]acetate
  参考文献：
  名称：

  Inhibitors of viral replication, their process of preparation and their therapeutical uses

  摘要：

  本发明涉及化合物及其在治疗或预防病毒性疾病，包括艾滋病（HIV）中的应用。

  公开号：

  EP2821104A1

文献信息

• METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS
  申请人：Novartis AG

  公开号：US20210387995A1

  公开（公告）日：2021-12-16

  The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as Cav1.2 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, and early repolarization syndrome.

  本公开提供了一种根据公式(I)的化合物或其药物可接受的盐，作为Cav1.2激活剂，用于治疗精神分裂症、双相情感障碍、重性抑郁障碍、物质使用障碍、多动症、费伦-麦克德米德综合症、孤独症谱系障碍、多发性硬化症、额颞叶痴呆、阿尔茨海默病、布鲁加达综合症、短QT综合症和早期复极化综合症。
• AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE
  申请人：Amgen Inc.

  公开号：US20140107109A1

  公开（公告）日：2014-04-17

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , R 1 , R 2 , R 3 , R 7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.

  本发明提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般的化学式I： 其中化学式I中的变量A4、A5、A6、A8、R1、R2、R3、R7和n在此独立地被定义。该发明还提供了包含这些化合物的药物组合物，以及这些化合物和组合物用于治疗与A-beta斑块形成和沉积相关的疾病和/或症状的对应用途，这些疾病和症状是由BACE的生物活性引起的。这种由BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。该发明还提供了化学式II的化合物及其亚式化合物，中间体和用于制备化学式I-II化合物的有用过程和方法。
• PHOSPHORESCENT EMITTERS
  申请人：XIA Chuanjun

  公开号：US20110204333A1

  公开（公告）日：2011-08-25

  Compounds including a ligand with a dibenzo-fused 5-membered ring substituent are provided. In particular, the compounds may be iridium complexes including imidazole coordinated to the dibenzo-substituted ligand. The dibenzo-fused 5-membered ring moiety of the ligand may be twisted or minimally twisted out of plane with respect to the rest of the ligand structure. The compound may be used in organic light emitting devices, particularly as emitting dopants in blue devices. Devices comprising the compounds may demonstrate improved stability while maintaining excellent color.

  提供了包括带有二苯并嵌合的5元环取代基的配体的化合物。具体来说，这些化合物可能是铱配合物，包括咪唑配位到二苯取代的配体上。配体的二苯嵌合的5元环部分可能与配体结构的其余部分扭曲或最小程度扭曲。该化合物可用于有机发光器件，特别是作为蓝光器件中的发射掺杂剂。包含这些化合物的器件可能表现出改善的稳定性，同时保持优秀的颜色。
• [EN] PENTACYCLIC DERIVATIVES AS ZIKA VIRUS INHIBITORS<br/>[FR] DÉRIVÉS PENTACYCLIQUES EN TANT QU'INHIBITEURS DU VIRUS ZIKA
  申请人：[en]GILEAD SCIENCES, INC.

  公开号：WO2022246109A1

  公开（公告）日：2022-11-24

  Provided herein are compounds of Formula (I): wherein the various substituents are defined herein.